Cefditoren is a broad-spectrum third-generation cephalosporin antibiotic typically used to treat bacterial infections of the skin and respiratory tract. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.
- Mechanism
- Curator reviewed
The bactericidal activity of cefditoren results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Cefditoren is stable in the presence of a variety of b-lactamases, including penicillinases and some cephalosporinases.
- Primary indication
- For the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of microorganisms in acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia,...Curator reviewed · 6 structured indications
- Formula / weight
- C19H18N6O5S3 · 506.578 g/mol (avg)
- First approval
- United States, 2008
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
KMIPKYQIOVAHOP-YLGJWRNMSA-NSMILES[H][C@]12SCC(\C=C/C3=C(C)N=CS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=OTargets
What you can answer from here — as of September 16, 2026
3Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Cefditoren, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account